The size of the Asia Pacific Regenerative Medicines Market is expected to reach USD 5.21 billion by 2025 from USD 1.72 billion in 2020, growing at a CAGR of 28.90% during the forecast period.
Stem cells that offer the potential to replace cells and tissues to treat a variety of diseases and disorders, including spinal cord injury, arthritis, and Parkinson's disease create immense possibilities in APAC Regenerative Medicines Market. Also, stem cell and gene therapy offer a potential treatment for the disease, rather than long-term treatment, and shifts focus from treatment to treatment. The application of stem cell technology in disease treatment has ultimately increased adoption rates. Therefore, the growing popularity of stem cell technology and increased research is expected to move the market forward during the forecast period.
Government initiatives supporting advanced therapies, rising focus of foreign pharmaceutical companies to invest in the Asian healthcare industry, a growing number of patients suffering from chronic disease conditions, and increasing demand for organ transplantation are driving the growth of the Asia Pacific Regenerative Medicines Market.
The increasing accidents and bone defects are the major factors driving the Asia-Pacific (APAC) Regenerative Medicines Market. Some tissue engineering research is also ongoing to develop bone graft substitutes with the help of regenerative medicine. Therefore, with the new development of bone grafts, the market is expected to grow over the forecast period.
However, scarcity of skilled professionals, the poor penetration rate of advanced healthcare treatment solutions, and difficulties to maintain the regenerative medicines, and the requirement of a high budget for the development of cell-based products (such as stem cells) are restraining the growth of Asia Pacific Regenerative Medicines Market.
This research report segmented and sub-segmented into the following categories:
In Japan, the Ministry of Health, Labor and Welfare approved the Regenerative Medicine Act in April 2013, promoting clinical development of regenerative and cell-based therapies as well as the Chinese government has accepted several studies related to human embryonic stem cells and has encouraged researchers to explore the clinical potential of these cells in China. Also, increasing healthcare needs, changing lifestyles, and aging populations are other factors that have a positive effect on regional market growth.
The government of India mainly promotes research and development in regenerative medicine and business development innovations. These organizations assure public empowerment and revolution in healthcare. In this market, challenges remain on achieving regulatory error, feasible outputs and fair impacts. As per the researchers, the strong social contract is needed in healthcare to increase the participation for the treatments. Also, an authority of private nanomaterials, cord blood banking and 3D bioprinting needed more attention. In the Covid-19 outbreak, there is an increasing demand to develop a new vaccine using regenerative medicine. The research going on in India concludes that the stem cell repels the viral infection due to the presence of interferon-gamma invigorated qualities (ISGs). Growing population and the responses from the patients or participants for the research will drive the growth of the regenerative medicine market in India. Loosely structured framework of the government will have a bad effect on the growing market growth.
According to Chinese scientist, patients who have participated in the experiment of Mesenchymal stem cells injections which is derived from the human umbilical cord can protect the Covid-19 patients those who are having dangerous inflammation and serious breathing problems. A growing community of clinical researchers and physicians in China will grow the regional regenerative medicine market by providing treatments like SARS-CoV-2 for such pandemics in the future. Stringent rules and regulations by the government in approving new drugs is slowly impeding the demand of the market. In recent days, researchers have immediately launched some clinical trials, and the results show that the curative effect of drugs on patients is increasing this kind of researches will drive the growth of the market in the forecast period.
To control the mortality rate during the Covid-19 pandemic, Japanese researchers induced Japanese Encephalitis Vaccine (JEV) to protect the patient especially vulnerable population like those who are in morbid condition and elder to tackle the Covid-19. The rising chronic diseases and cardiovascular diseases will drive growth in the forecast period. Recently the aged population and the population under 18 is capturing more diseases is the challenge.
Australia stated that the survival rate increased to 83% with mesenchymal stem cells (MSCs) treatment procedure for patients with acute respiratory distress syndrome (ARDS). Australian regenerative medicine market has necessary fundaments to become a competitive, profitable and global industry and extending a big vision towards the future which will be helpful for the growth of the regional regenerative medicine market in the coming years. The high budget requirement for the research is a restraint on this market. It will affect further research studies in the future.
South Korea is researching on the Covid-19 places heavy emphasis on regenerative medicine. The system for stem-cell researches in South Korea is less strict than those in other countries. The country is looking to enhance the research and development in regenerative medicine and ensure its consistency of their regenerative medicine. The government gives funding for the researches in South Korea is increasing, and this is to fuel the growth rate of the market. The less presence of the skilled professionals in the country and the maintenance of the regenerative products is the threat for the market growth.
Noteworthy companies operating in the APAC Regenerative Medicines Market profiled in this report are Vertex Pharmaceuticals Incorporated (U.S.), Acelity L.P. Inc. (U.S.), Celgene Corporation (U.S.), StemCells, Inc. (U.S.), Organogenesis Inc. (U.S.), NuVasive, Inc. (U.S.), Vericel Corporation (Genzyme) (U.S.), Japan Tissue Engineering Co., Ltd. (Japan), Cytori Therapeutics Inc. (U.S.), Advantagene, Inc. (U.S.) and Mesoblast Ltd. (Australia)
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.2.2 Cell-Based Products
126.96.36.199 Autologous Cell-Based Products
188.8.131.52 Allogeneic Cell-Based Products
5.2.3 Acellular Products
5.3.2 Cell Therapy
5.3.3 Gene Therapy
5.3.4 Tissue Engineering
5.4.2 Orthopedic & Musculoskeletal Spine
5.4.5 Central Nervous System
5.4.8 Other Applications
6. Geographical Analysis
6.1 North America
6.1.2 United States
6.3.6 Soth Korea
6.4 Latin America
6.5 Middle East & Africa
6.5.2 Middle East
6.5.3 South Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Vertex Pharmaceuticals Incorporated (U.S.)
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Acelity L.P. Inc. (U.S.)
8.3 Celgene Corporation (U.S.)
8.4 StemCells, Inc. (U.S.)
8.5 Organogenesis Inc. (U.S.)
8.6 NuVasive, Inc. (U.S.)
8.7 Vericel Corporation (Genzyme) (U.S.)
8.8 Cytori Therapeutics Inc. (U.S.)
8.9 Advantagene, Inc. (U.S.)
8.10 Mesoblast Ltd. (Australia)
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
a) List of Tables
b) List of Figures